stockrow
Saturday 7 November 2026
Export KALA’s income statement to Excel — free account
KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million.
- EPS
- +99.9%
- Free cash flow
- +80.2%
Quarter to June 2026, against a year earlier
0.16
0.01
+6.67%
Follow KALA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.65 | 3.03 | 5.63 | 4.70 | |
Current Ratio |
0.75 | 3.81 | 7.91 | 6.88 | |
Net Debt/EBITDA |
(1.05) | 0.67 | 4.86 | 4.20 | |
Debt/Assets |
113.55% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
(3.28) | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.44 | (6.64) | 1.79 | 0.97 | |
Capex/Depreciation |
(0.06) | 0.00 | — | — | |
Interest Coverage |
(7.52) | (72.52) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(77.25) | (27.95) | (0.24) | (0.08) | |
Capex per Share |
(0.11) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(77.36) | (27.95) | (0.24) | (0.08) | |
Cash per Share |
149.83 | 46.36 | 0.74 | 0.39 | |
Shareholders Equity per Share |
(61.54) | 42.92 | 0.91 | 0.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(61.54) | 42.92 | 0.91 | 0.48 | |
Free Cash Flow |
(10.89) | (4.56) | (2.89) | (1.53) | |
Working Capital |
(8.30) | 7.00 | 10.76 | 9.04 | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
Net Current Asset Value |
(9.41) | 7.00 | 10.76 | 9.04 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
0.81 | 0.81 | 0.99 | 0.90 | |
Average Assets |
39.55 | 32.49 | 30.29 | 23.32 | |
Average Common Equity |
(0.90) | 9.66 | 8.23 | 2.92 |
Columns are period end dates · fundamentals updated 26 Oct 2026